Voyager Therapeutics, Inc. VYGR
We take great care to ensure that the data presented and summarized in this overview for Voyager Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VYGR
View all-
Armistice Capital, LLC New York, NY4.67MShares$37 Million0.59% of portfolio
-
Black Rock Inc. New York, NY4.4MShares$34.8 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.92MShares$31 Million1.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$25.6 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.29MShares$18.1 Million0.1% of portfolio
-
State Street Corp Boston, MA1.75MShares$13.8 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.11MShares$8.74 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.04MShares$8.24 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA972KShares$7.69 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT794KShares$6.28 Million0.01% of portfolio
Latest Institutional Activity in VYGR
Top Purchases
Top Sells
About VYGR
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VYGR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 02
2024
|
Alfred Sandrock President and CEO |
SELL
Open market or private sale
|
Direct |
12,115
-3.62%
|
$109,035
$9.86 P/Share
|
|
Apr 02
2024
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,357
-1.15%
|
$12,213
$9.88 P/Share
|
|
Apr 01
2024
|
Toby Ferguson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+50.0%
|
-
|
|
Feb 21
2024
|
Alfred Sandrock President and CEO |
SELL
Open market or private sale
|
Direct |
13,033
-3.75%
|
$91,231
$7.46 P/Share
|
|
Feb 21
2024
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,966
-3.24%
|
$27,762
$7.45 P/Share
|
|
Feb 21
2024
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,365
-3.7%
|
$23,555
$7.47 P/Share
|
|
Feb 21
2024
|
Peter P. Pfreundschuh Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,764
-2.1%
|
$26,348
$7.46 P/Share
|
|
Feb 20
2024
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
602
-0.66%
|
$4,214
$7.68 P/Share
|
|
Feb 09
2024
|
Sandell Jacquelyn Fahey Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,000
+25.2%
|
-
|
|
Feb 09
2024
|
Alfred Sandrock President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+27.2%
|
-
|
|
Feb 09
2024
|
Robin Swartz Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+29.01%
|
-
|
|
Feb 09
2024
|
Todd Alfred Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,500
+29.59%
|
-
|
|
Feb 09
2024
|
Peter P. Pfreundschuh Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+14.32%
|
-
|
|
Jan 17
2024
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,266
-2.33%
|
$8,862
$7.18 P/Share
|
|
Jan 17
2024
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,543
-3.4%
|
$17,801
$7.15 P/Share
|
|
Oct 03
2023
|
Peter P. Pfreundschuh Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,567
-8.32%
|
$81,402
$6.99 P/Share
|
|
Oct 01
2023
|
Sandell Jacquelyn Fahey Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,000
+50.0%
|
-
|
|
Sep 15
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,500
-16.19%
|
$84,000
$8.16 P/Share
|
|
Sep 15
2023
|
Todd Alfred Carter Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.16%
|
$10,000
$2.85 P/Share
|
|
Jul 06
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,500
-8.41%
|
$55,000
$10.8 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 446K shares |
|---|---|
| Exercise of conversion of derivative security | 10K shares |
| Open market or private sale | 76.6K shares |
|---|